CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Efprezimod alfa +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02650895
NCT02650895Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jan 8, 2016·Updated Jan 12, 2023

In Brief

A Phase 1 clinical trial evaluating Efprezimod alfa and Saline for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses of efprezimod alfa in healthy adult participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 8, 2016
Enrollment StartJun 2, 2014
Primary CompletionJan 15, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.5 years ago

Interventions

Efprezimod alfabiological

Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain

Salinedrug

0.9% sodium chloride